Not provided
Not provided
| ID | Type | Description | Link |
|---|---|---|---|
| H-1-2010-130 | Registry Identifier | The Danish National Committee on Biomedical Research Ethics |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Class |
|---|---|
| University of Copenhagen | OTHER |
| Steno Diabetes Center Copenhagen | OTHER |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
The purpose of this study is to describe the incretin effect and postprandial incretin response in patients with MODY2 and MODY3 and a group of matched healthy subjects. In sulphonyl urea treated subjects the purpose is also to compare the incretin effect with and without treatment. In healthy subjects the purpose is also to investigate the incretin effect under increased levels of endogen incretin hormones.
Comparison of of insulin secretion (AUC) during the experimental days. Furthermore a comparison of GIP, GLP1 and glucagon responses as well as plasma glucose levels.
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| MODY2 | Also called GCK (glucokinase) MODY. They have a specific mutation in the GCK gene. |
| |
| MODY3 | Also called HNF1 alfa MODY. They have a specific mutation in the HNF1 alfa gene. |
| |
| Healthy control subjects |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Oral Glucose Tolerance Test (OGTT) | Other | 50g waterfree glucose dissolved in 300ml water consumed over 5 min. |
|
| Measure | Description | Time Frame |
|---|---|---|
| Incretin effect | The difference in insulin responses, as assessed by the area under curve (AUC) for plasma insulin and C-peptide concentrations, during the two different glucose stimuli: OGTT and isoglycemic iv glucose infusion aswell as after a test meal in MODY-patients compared to healthy control subjects. | Within 1 year |
| Measure | Description | Time Frame |
|---|---|---|
| Plasma GLP1 response | Comparing GLP1 responses of the different experimental days, compared to healthy control subjects. | Within 1 year |
| Plasma GIP response | Comparing GIP responses of the different experimental days, compared to healthy control subjects. |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Genetically well-charaterized MODY2 and MODY3 patients at Hagedorn Research Institute/Steno Diabetes Center
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Signe H Ă˜stoft, MD, phd stud | Diabetes Research Division, University Hospital Gentofte, Denmark | Principal Investigator |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Diabetes Research Division, Gentofte University Hospital, Niels Andersens vej 65, opgang 40, 2. | Hellerup | 2900 | Denmark |
| PubMed Identifier | Type | Citation | Retractions |
|---|---|---|---|
| 25953829 | Derived | Ostoft SH, Bagger JI, Hansen T, Hartmann B, Pedersen O, Holst JJ, Knop FK, Vilsboll T. Postprandial incretin and islet hormone responses and dipeptidyl-peptidase 4 enzymatic activity in patients with maturity onset diabetes of the young. Eur J Endocrinol. 2015 Aug;173(2):205-15. doi: 10.1530/EJE-15-0070. Epub 2015 May 7. |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Buffy coat
|
| iso glycaemic intravenous (iv) glucose infusion (IIGI) | Other | 20% glucose |
|
|
| Meal test | Dietary Supplement | Energy drink, 350ml (525 kcal: 65 g carbohydrates, 20 g fat and 21 g protein) |
|
|
| Sitagliptin | Other | Healthy control subject are given an acute dosage of 100mg the evening before the experimental day, and the same morning in order to increase levels of endogen incretin hormones |
|
|
| Incretin effect on sulphonyl urea treatment | Other | Subject with MODY who are treated with sulphonyl urea are investigated without medication break prior to examination. |
|
| Within 1 year |
| Plasma glucagon response | Comparing glucagon responses of the different experimental days, compared to healthy control subjects. | Within 1 year |
| ID | Term |
|---|---|
| C562772 | Mason-Type Diabetes |
| D003920 | Diabetes Mellitus |
| ID | Term |
|---|---|
| D044882 | Glucose Metabolism Disorders |
| D008659 | Metabolic Diseases |
| D009750 | Nutritional and Metabolic Diseases |
| D004700 | Endocrine System Diseases |
Not provided
Not provided
| ID | Term |
|---|---|
| D005951 | Glucose Tolerance Test |
| D000068900 | Sitagliptin Phosphate |
| ID | Term |
|---|---|
| D001774 | Blood Chemical Analysis |
| D019963 | Clinical Chemistry Tests |
| D019411 | Clinical Laboratory Techniques |
| D019937 | Diagnostic Techniques and Procedures |
| D003933 | Diagnosis |
| D003940 | Diagnostic Techniques, Endocrine |
| D008919 | Investigative Techniques |
| D014230 | Triazoles |
| D001393 | Azoles |
| D006573 | Heterocyclic Compounds, 1-Ring |
| D006571 | Heterocyclic Compounds |
| D011719 | Pyrazines |
Not provided
Not provided